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studieswill be essential for developing anunderstanding of dietary lipid
processing and facilitate the identiﬁcation of new therapeutic targets.
We have developed an assay to observe lipid absorption at the single
enterocyte level using lipophilic dyes in zebraﬁsh larvae that express
ﬂuorescent fusion proteins. When larvae are fed a high fat diet,
enterocytes accumulate lipid droplets that can be visualized in real-
time in live animals. The intracellular fate of these newly absorbed lipids
was examined by co-localization of well-characterized ﬂuorescent
fusion proteins important for endocytosis and trafﬁcking of lipids.
doi:10.1016/j.ydbio.2008.05.338
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Valproic acid (VPA) is a short-chain fatty acid that is widely used
to treat epilepsy and bipolar disorder. However, VPA treatment during
pregnancy is associated with neural tube defects, cardiac malforma-
tions, craniofacial abnormalities, and limb defects. The mechanism by
which these developmental defects occur is poorly understood. Our
lab has shown that VPA directly inhibits histone deacetylases
(HDACs). We are using Xenopus laevis as a model system to study
the consequences of VPA mediated HDAC inhibition in early
development. Administering a therapeutically relevant dose of VPA
(1–2 mM) to gastrulating Xenopus embryos causes heart looping
abnormalities, pericardial edema, and a signiﬁcant reduction in
circulating red blood cells. However, overall development appears
essentially normal, and markers of dorsal and lateral mesoderm are
grossly normal, suggesting a relatively restricted effect of VPA under
this treatment regimen. We have found that VPA signiﬁcantly reduces
expression of the hematopoietic marker Xenopus acute myeloid
leukemia (Xaml/runx1) speciﬁcally in the ventral blood islands. The
reduction of Xaml expression can be recapitulated by another HDAC
inhibitor, Trichostatin A (TSA), but not by valpromide (VPM), a
structural analog of VPA that does not inhibit HDACs, suggesting that
the effects of VPA are mediated through HDAC inhibition. Our future
studies will focus on understanding the mechanism by which VPA
and HDAC inhibitions disrupt erythropoiesis during early
development.
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